ArticleJournal of neurology2024

Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.

Albulena Bajrami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.